Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on NASDAQ Uplisting
New York, NY – February 27, 2015 – (Global Newswire) – Nationally recognized securities and
corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the discovery and development of antiviral therapies, in the Company’s uplisting to the NASDAQ Capital Market. The uplisting is effective for trading on February 27, 2015 and ContraVir’s common stock will trade under its existing stock symbol: “CTRV”.
The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.
Media Contact:
pr@srf.law
(212)-930-9700
SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.
Latest posts by Sichenzia Ross Ference Carmel LLP (see all)
- Sichenzia Ross Ference Carmel LLP Represents Safe & Green Holdings Corp. in a $8 Million Private Placement - April 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents FatPipe, Inc. in Closing of $4 Million Initial Public Offering - April 10, 2025
- Sichenzia Ross Ference Carmel Names Matilde Tysz as Chief Strategy Officer - April 9, 2025
